Livmoniplimab

DB18939InvestigationalProtein Based Therapies

Livmoniplimab is under investigation in clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination...

Mechanism: Pharmacologically active on Transforming growth factor beta activator LRRC32 and Transforming growth factor beta-1 proprotein
Curator reviewed
Also known as: Immunoglobulin g4 (234-proline), anti-(human protein garp-transforming growth factor .beta.1 complex) (human monoclonal abbv-151 .gamma.4-chain), disulfide with human monoclonal abbv-151 .kappa.-chain, dimer
Code names: ABBV-151 · ARGX-115

Resolves to

Compound

UNII42SH7JCD82CAS2412004-88-5

Targets

Q14392LRRC32P01137TGFB1

What you can answer from here — as of June 12, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Livmoniplimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account